REG - RTW Biotech Opp. - Director Declaration

RTW Biotech OpportunitiesAnnouncement

31/05/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe6721Qa&default-theme=true

RNS Number : 6721Q  RTW Biotech Opportunities Ltd  31 May 2024

LEI: 549300Q7EXQQH6KF7Z84

31 May 2024

RTW Biotech Opportunities Ltd
(the "Company")

Director Declaration

In accordance with LR 9.6.14, the Company announces that Paul Le Page, a
non-executive director of the Company, will join the board of Sequoia Economic
Infrastructure Income Fund Limited, as a non-executive director with effect
from 7 June 2024.

For Further Information:

 

 RTW Investments, LP                           +44 (0)20 7959 6361

                                               biotechopportunities@rtwfunds.com
 Woody Stileman, Managing Director

 Krisha McCune, Director, Investor Relations

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNBGGDURGXDGSB